Category

Compounding and compliance

58 plain-language articles on compounding and compliance — the physiology, the compounds, and what the evidence actually shows.

58 articles

503A vs 503B: what "compounded" actually meansYou're looking at two pharmacy websites side by side and they both have peptides for sale. One mentions 503A. The other mentions 503B. You don't know what either of those numbers means, and you don't want to be the kind of person who asks. So you squint at the fine print, look for a trust badge or a seal, and eventually just pick the one with the cleaner website.8 min read The anti-aging clinic phenomenon — from hormone-replacement to peptide protocolsA full-page advertisement in a trade publication from 2002 shows a physician in a white coat standing next to a silver-haired couple who look ten years younger than they probably are. "Turn Back the Clock," the headline says. The American Academy of Anti-Aging Medicine — A4M — is holding its annual World Congress, the largest gathering of what it calls "longevity physicians" in the world. Thousands of physicians will attend. They will receive continuing medical education credit. They will hear presentations on growth hormone optimization, testosterone and estrogen replacement, telomere biology, dietary supplement protocols, and the emerging category of peptide interventions. They will return to their practices with a new clinical identity: anti-aging medicine. A subset of them will open dedicated clinics.10 min read The history of compounding pharmacy — from the 1990s to the modern peptide landscapeOn a Friday in September 2012, a patient in Tennessee developed what his physicians initially mistook for bacterial meningitis. By the weekend, clinicians at Vanderbilt University Medical Center were confused: the infection was not responding to antibiotics, the imaging was unusual, and the spinal fluid was not showing the bacterial pattern they expected. By the following week, they had identified the organism. It was Exserohilum rostratum, a common mold found in soil and plant matter. It had no business being in anyone's spinal cord. Tracing backward, investigators found the same fungus in patients in other states — Tennessee, Michigan, Virginia, Florida — all of whom had received epidural steroid injections for back pain in recent weeks. All of them had received the same methylprednisolone acetate preparation. All of it came from one facility in Framingham, Massachusetts: the New England Compounding Center.10 min read Compounding pharmacy quality variation — what's actually different from one pharmacy to anotherYou assume a licensed pharmacy is a licensed pharmacy. The license hangs on the wall, the state board approved the operation, the pharmacist passed their boards. The peptide you're getting from a licensed compounding pharmacy in one state should be the same quality as the peptide from a licensed pharmacy in another state. That assumption is wrong, and the degree to which it's wrong is something the wellness marketing around compounded peptides almost never discusses.10 min read Cycling peptides — when to come off, when to stay onSomewhere in the online conversation about peptides, "cycle" became a universal instruction. Take it for twelve weeks, take four weeks off. Or five weeks on, two weeks off. The specific numbers vary, but the underlying assumption doesn't: everything needs to be cycled, and cycling is what keeps it working. If you believe that, you'll apply it uniformly, which means you'll cycle things that don't need cycling and fail to cycle things that do. The rule sounds responsible. It's actually a blunt instrument applied to a situation that requires precision.8 min read What the FDA actually says about compounded peptidesYou've read something online that says compounded peptides are "banned by the FDA." You've also read something that says the FDA has nothing to do with compounded medications and it's all perfectly legal. Both of those things feel partially true and you can't reconcile them into a single coherent picture. The confusion is understandable. It's also fixable — because the FDA's actual position is precise, if you read it carefully rather than reading it through the filter of whoever was alarmed or reassured enough to write about it.9 min read FDA enforcement actions against peptide companies — what's happened and what it teachesThe warning letter arrives and the company's website goes dark. Maybe the FAQ page stays up for a few days with an explanation about "regulatory review." Maybe the domain just stops loading. Users who have been relying on that vendor for their supply find themselves scrambling, posting in forums, asking where else to go. The regulatory action that triggered it was months or years in development. For the users, it arrives as a sudden disruption. They had no warning because the vendor had no incentive to provide one.10 min read Where to start if you're considering peptides for the first timeYou've read enough to be genuinely interested and not quite sure what to do with that. The mechanisms make sense. The research is more substantive than you expected. There are compounds that seem directly relevant to what you've been experiencing. You want to know what the first step actually is.9 min read Finding a physician who's knowledgeable about peptidesWhat you want isn't a second medical system running parallel to the one that has your records and knows your history. You want someone who understands peptide pharmacology and can integrate that knowledge with the rest of your care — who knows what you're taking, can monitor it intelligently, and can talk to your cardiologist or gynecologist if something unexpected comes up. That's a reasonable thing to want. It's also genuinely hard to find, and understanding why helps you search more effectively.9 min read Gray market vs compounding pharmacy — the supply chain distinction that matters mostAnyone who has spent time evaluating peptide options has arrived at the same question eventually, even if they didn't frame it this way: where is this actually coming from, and what does that mean? Two websites side by side, similar compound names, similar descriptions of mechanisms and expected effects, sometimes similar visual design. One costs substantially more and requires a prescription and a clinical consultation. One costs less, ships immediately, no prescription required. The price and convenience comparison is obvious. The supply chain comparison — the question of what these two purchase paths actually represent in terms of quality, legality, and accountability — is not stated anywhere on either site in a way that makes it easy to evaluate.4 min read How to evaluate a peptide clinic — what to look for and what to avoidYou open the search results and there are dozens of them. Anti-aging clinics, longevity clinics, wellness optimization practices, men's health platforms, women's hormone centers. Some have polished websites with before-and-after photos and testimonials about transformation. Some have clinical-looking interfaces with intake forms and physician names in small print. Some are primarily Instagram presences with a "consult" button. They vary dramatically in what they are, what they'll prescribe, what oversight they provide, and what your experience as a patient will actually look like. There's no obvious way to tell from the outside which is which.6 min read How to read a peptide pharmacy's certificate of analysisYou get the PDF. It's four pages long, dense with numbers and abbreviations, and somewhere on page two there's a percentage — 98.7% — next to something called "assay." You assume that's good. You don't actually know what assay means, or what number would be bad, or whether you're even reading the column that applies to your vial. So you scroll to the bottom, confirm it says "pass" a few times, and call it done.7 min read How to actually start peptides — the framework that prevents most regretYou've done the reading. You've spent weeks going through forums, studies, clinical write-ups, and probably a few podcasts that oscillated between breathless enthusiasm and hedged disclaimers. You've arrived at a place where you believe some version of this is worth exploring for your specific situation. Now you're staring at the actual question, which is harder than it sounds: how do you actually begin, in the right sequence, without making the expensive mistakes that most people make?6 min read How to think about peptides — the framework before you choose any specific compoundYou've been reading for a while now. Maybe you came in through the GLP-1 article, or someone mentioned BPC-157 and you went looking, or you've been living in the library for an hour and have seventeen tabs open and a question that's growing faster than the answers. The research starts to feel urgent. You want to know which one. Which peptide, which protocol, which starting point.6 min read The legal landscape for peptides — what's actually allowedYou're looking at a peptide on a supplier's website. One site calls it a research chemical and notes it's not for human consumption. Another site offers the same compound through a telehealth clinic with a prescription. A third forum thread says you can order it internationally with no issues. Three descriptions of what sounds like the same molecule, and none of them is obviously lying. The regulatory landscape for peptides is genuinely complicated, and the confusion isn't manufactured — it reflects real fragmentation across FDA jurisdiction, compounding law, drug scheduling, and enforcement priorities. Understanding the actual framework helps you distinguish between legal pathways and those that simply haven't been enforced yet.4 min read Oral peptide delivery — the engineering breakthroughs that may transform peptide therapyThe first time most people hear they'll need to inject a peptide — weekly, subcutaneously, into the abdomen or thigh — there's a pause. Not everyone walks away. But some do, and more simply never start. The needle is a real barrier in a way that swallowing a pill isn't, and that barrier has shaped the entire history of peptide therapeutics: which drugs got developed, which patient populations were reachable, which indications were commercially viable. Insulin has required injection for a century. Most peptide drugs have followed the same path, for the same underlying reason.7 min read Oral vs injectable peptide bioavailability — what the route actually changesYou found a peptide you're interested in and then you found what appears to be an oral version of it, and the oral version is cheaper and obviously more convenient and you'd rather not inject yourself if you can avoid it. Before you order the capsules, there's a question worth asking. Not a rhetorical question. A pharmacological one: does this compound actually survive the trip from your mouth to your bloodstream in any meaningful quantity?6 min read The peptide budget question — what reasonable monthly spend looks likeYou've started doing the math and something isn't adding up. The clinical consultation was one cost, the labs were another, and now you're looking at the actual prescription and trying to figure out whether this number is reasonable, inflated, or if you're missing something about how this whole thing is priced. The range you've encountered — from discussions of $50-a-month protocols to clinics advertising programs at several hundred monthly — spans too wide to evaluate without some framework for what you're actually paying for at each level.8 min read The COA gaming problem — why "third-party tested" doesn't always mean what you thinkWhen a peptide company says "third-party tested," you probably picture an independent laboratory that received a sample of the exact product you're about to buy, ran it through meaningful analytical instruments, and confirmed that what's on the label is what's in the vial — correct identity, correct concentration, acceptable purity, and, for injectables, absence of the contaminants that matter for safety. That picture is accurate for some products. It is not accurate for a significant portion of the peptide market, and the gap between the marketing claim and the actual quality practice is large enough to affect decisions.9 min read Peptide drug interactions — what to flag with your prescribing providerYou've been on metformin and a statin for two years. You're about to start a peptide protocol — sermorelin, maybe BPC-157, possibly a GLP-1. Your prescribing provider is aware of the peptides. Your primary care doctor is aware of the metformin and statin. Neither provider has the full picture, and you're sitting with a list of compounds and a reasonable question: do any of these interact?9 min read Peptide harm reduction — the framework for those who will proceed regardlessYou've read the disclaimers. You know that clinician-supervised use through a licensed compounding pharmacy is the recommended path. You've decided you're going to proceed anyway — maybe because cost or access makes supervised use impractical, maybe because you've made a personal autonomy calculation, maybe because you've done enough research that you've decided the risk-benefit ratio is acceptable to you without formal oversight. This piece is not going to talk you out of that. It's going to tell you how to reduce the harm in the situation you've chosen.9 min read Peptide influencer conflicts of interest — what to know about the recommendations you're readingThe podcaster has been discussing BPC-157 for forty minutes. He explains the mechanism clearly — gut lining repair, tendon healing, angiogenesis — and his enthusiasm is real, or performs well as real. Near the end he mentions he's been using it for three months and his knee has never felt better. He gives a code. Ten percent off at the vendor he uses. He doesn't mention that the vendor is paying him a percentage of every sale that code generates. He doesn't mention that when he signed the affiliate deal six months ago, he agreed to produce a certain number of favorable mentions per quarter.7 min read The peptide influencer problem — when "research" becomes marketingA YouTube video goes up. Forty-three minutes, thumbnail of a shirtless man in his late forties who looks the way people look in magazines rather than in life. The title is something like "My Full Peptide Stack — What I Take, Doses, Results After 6 Months." By the end of the first week it has six hundred thousand views. The comment section is a mix of people asking "where do you source this," people sharing their own results with the same compounds, and people posting disclaimers about consulting a physician that read, in context, like ritual rather than advice. In the description, there are affiliate links to a peptide vendor. There is a code for ten percent off. The creator does not disclose whether the code generates a commission, though it does.10 min read When peptide use causes injury — the harms the wellness world doesn't talk aboutThe wellness forum post reads like a thousand others until it doesn't. Someone describes a lump at an injection site that got warm, then red, then hard, then large enough that they went to urgent care. The urgent care doctor lanced it. The wound packed. A week of oral antibiotics. Then a second course. They never mentioned the peptides to the doctor because they didn't know how — didn't know if peptides would complicate the treatment, didn't know what the doctor's reaction would be. They logged the incident in the forum as a cautionary tale about injection technique and moved on.10 min read Peptides and insurance coverage — what's covered, what isn't, and whyYou fill your metformin at the pharmacy for eleven dollars. The compounded BPC-157 you just started costs two hundred and forty dollars a month out of pocket, and your insurance card sits in your wallet doing nothing. You've tried submitting the receipt anyway. The claim came back denied before you'd finished the paperwork. The gap between what insurance covers and what the peptide space offers isn't an accident — it's structural, and understanding the structure helps you figure out where to push and where to stop wasting time.9 min read Peptide library navigation by symptom — finding the relevant researchYou didn't arrive here with a compound in mind. You arrived with a symptom — or a cluster of them, the kind that resists clean categorization. Fatigue that sleep doesn't fix. A cognitive flatness that started somewhere in your 40s and hasn't lifted. Recovery that takes longer than it used to. A metabolism that seems to have renegotiated its terms without your input. You started looking for information and found a landscape with a lot of compound names and not much of a map.9 min read The peptide overconsumption pattern — when interventions become identityIt started with one thing. BPC-157 for the shoulder that had been nagging since the fall. The shoulder improved — or seemed to — and then someone in the forum mentioned ipamorelin for sleep, and the sleep did feel different after a few weeks, and then there was a podcast about thymosin beta-4 and peptide stacking for recovery, and now the spreadsheet has seven columns and a bi-weekly review schedule and more time goes into managing the protocol than goes into the training the protocol is supposed to support.9 min read Peptide protocol troubleshooting — when something isn't workingSix weeks in and nothing has changed. Or something changed but not what you expected, and now you're trying to decide whether to add a compound, switch compounds, increase the dose, or conclude that peptides just don't work for you. Before any of those moves, there's a prior question that most people skip: is the protocol actually not working, or are you assessing it incorrectly?9 min read Tracking peptide protocols — what to log and why it mattersSix weeks into the protocol and someone asks you how it's going. You say you think you feel better. Maybe your sleep is improved. Your gym recovery might be faster — hard to say. You haven't taken any measurements, didn't get labs before you started, and don't have a symptom score from week zero to compare against week six. You're not actually answering the question. You're narrating a general feeling, which is a different thing entirely. The problem isn't the peptide — it's that you started an experiment without setting up the conditions that would let you evaluate the result.9 min read Peptide pulsing and microdose protocols — what they are and what evidence supports themYour prescribing provider suggests starting a GLP-1 at a lower dose than standard. Or the protocol sheet says five days on, two days off. Or the documentation you're reading recommends cycling a growth hormone secretagogue for three months and pausing. You're not sure whether this is standard practice, creative optimization, or something invented by the internet. The honest answer is that it depends on the compound — and that the rationale behind non-daily dosing is more grounded in biology than it might appear, even when the specific protocols outrun the formal evidence.9 min read Peptide realistic timelines — what to actually expect, whenYou read the protocol description and something says "noticeable effects within days." You start, you track carefully, and two weeks in you're not sure if anything is happening. You're trying to figure out whether this is normal — a waiting game you need to play out — or a signal that this compound isn't working for you and you should reassess. The uncertainty is uncomfortable, and it's entirely predictable, because the timeline language most people encounter before starting is almost never honest about what biology actually requires.8 min read The regulatory future for peptides — what's coming and what it meansThe access to compounded peptides that many people take for granted right now was not designed to be permanent. It exists because of a specific regulatory structure — the compounding pharmacy framework — that was built for specific purposes, and the conditions that made that framework hospitable to the current range of compounded peptides are actively shifting. The question isn't whether the regulatory environment for peptides will change. It's how fast, in what direction, and what a thoughtful response looks like for the people who are using or considering using compounded peptides now.10 min read Peptide research fraud and questionable studies — what to know about the integrity of the literatureIn 2015, the Open Science Collaboration published the results of an effort to reproduce 100 studies from three top psychology journals. The original papers had all been published in peer-reviewed outlets, passed editorial and reviewer scrutiny, and entered the scientific record as established findings. The reproducibility project, which used the original study authors' materials and methods wherever possible, found that only 36 of the 100 studies replicated with statistical significance. The scientific community absorbed this finding with varying degrees of alarm, but the direction of the conclusion was not disputed: a substantial fraction of published research, even in prominent journals, does not reproduce when someone else tries it. This is not a peripheral problem in science. It is central to how the enterprise actually works, which is to say imperfectly, with self-correction mechanisms that operate more slowly than publication mechanisms and with significant variation in how rigorous any given piece of research actually is.10 min read Route comparison — subcutaneous vs intramuscular vs intravenous for peptidesThe compounding pharmacy ships the vials and includes no instructions about where to inject. You've watched three videos on YouTube, each of which says something slightly different, and you have a syringe in your hand and you're not confident you know what you're doing. The route question — subcutaneous or intramuscular — feels like a technical detail. It isn't. Route of administration changes the pharmacokinetics of a compound: how fast it enters the bloodstream, how high the peak concentration gets, how long it stays active, and sometimes whether it gets to the right place at all.9 min read Peptide stacks for longevity vs performance — different goals, different combinationsYou're 48. You train four days a week, you sleep reasonably well, your labs are broadly fine, and you've been reading about peptides for six months. You have a list of compounds and no coherent framework for how they fit together. Someone told you BPC-157 was good. Someone else said Epitalon was what you actually needed. A forum thread convinced you that Ipamorelin plus CJC-1295 was the move, but then another thread contradicted it with an argument about IGF-1 and cancer risk that you haven't been able to shake. The problem isn't information. You have too much information. The problem is a framework for understanding what you're actually trying to do.10 min read The philosophy of peptide stacking — when one + one equals more than two, and when it equals lessYou've been reading the peptide literature long enough to notice a pattern. The protocols get larger over time. What started as a single compound becomes a stack. The stack acquires additions. You're now looking at someone's ten-compound regimen listed on a forum, followed by testimonials about transformative results, and you're trying to figure out whether the logic holds — whether more is actually more — or whether something else is happening.10 min read Stacking peptides without redundancy — the overlap nobody talks aboutThe logic feels obvious at first. You find one peptide that seems to be doing something useful, and then you find another one, and then you think: why wouldn't I take both? More inputs, more outputs. It's the same reasoning that leads people to take five supplements when one would have done the work — not because they're irrational, but because when something is working, the instinct is to add more things that might also work.8 min read Peptide storage and handling — what affects stability and potencyThe vial is sitting in the refrigerator door. You put it there because that's where you put things you want to remember — condiments, leftovers worth finishing, small items that benefit from being visible every time the fridge opens. It's a reasonable instinct. It's also, for many peptide preparations, not quite the right place. The difference between the door and the middle shelf sounds trivial. For a compound whose potency depends on staying within a narrow temperature range, it's not.7 min read When to choose peptides vs traditional approaches — the meta-decision frameworkYou've been reading about peptides long enough that you've started wondering whether you're looking at a legitimate part of modern medicine or a sophisticated version of the supplement industry's tendency to package hope in molecular language. That skepticism is healthy. It's also incomplete. The honest answer is that peptides occupy a real but specifically bounded place in the clinical landscape, and the question isn't whether they belong there — they do — but when they're the right tool and when something else is.9 min read Peptides for prevention vs treatment — when each frame appliesYou've been reading about BPC-157 for three weeks. Your knee tendinopathy is real — it's been limiting your training for six months — but you've also found yourself three tabs deep into longevity stacks and wondering whether you should be taking something for your gut, your cognition, your aging generally. The original problem is concrete. The prevention rationale is vaguer. Somewhere in the research you noticed that the distinction between those two framings matters, and you're right that it does, but you haven't found anyone who explains why.10 min read Peptides in pediatric and adolescent contexts — what's appropriate and what isn'tYour child is twelve, and something isn't adding up. He's significantly shorter than every peer and his pediatrician has mentioned growth hormone deficiency as a possibility. You've been doing research, as you do, and now you've landed in a corner of the internet where people discuss peptide protocols for adults, and you're wondering if any of it is relevant to what your son might need. Or maybe your daughter is fifteen, an athlete, and a coach mentioned that her recovery might benefit from something. Or you've read about GLP-1 medications for weight management and you're wondering whether there's an appropriate conversation to have about your thirteen-year-old.9 min read Peptides vs FDA-approved medications — the honest comparisonYou're looking at two columns. One column has your medications — the things with insurance codes, the things your primary care provider prescribed, the things that come in branded packaging from a regulated pharmacy. The other column has peptides — the things with compelling mechanisms, the things the optimization world talks about, the things you're injecting from a small vial your compounding pharmacy mailed you. You want to know whether these two things belong in the same conversation, whether one can substitute for the other, and whether anyone in the medical establishment is going to tell you something honest about how the two compare.10 min read Peptides vs supplements — when to escalate and when supplements are enoughYou've been taking supplements for years. Vitamin D, fish oil, magnesium, maybe a B-complex, possibly a few things you found in the back of a cabinet whose original purpose you've half-forgotten. You feel generally okay but not quite the way you want to feel, and the gap between okay and genuinely functional has started to seem like something worth addressing more deliberately. Someone mentions peptides. You pull up some information, the mechanisms sound compelling, the protocols look complex and clinical and you're not sure if you're ready for that, and you're also not sure if what you've been doing is actually covering the territory you think it's covering.10 min read Peptides vs supplements vs medications — the budget allocation questionYou have some amount of money you're willing to spend on your health, and you're trying to figure out where it goes. The options span an enormous range: a ten-dollar bottle of vitamin D from the pharmacy, a thirty-dollar creatine tub, a sixty-dollar monthly statin prescription, a two-hundred-dollar peptide protocol, a five-hundred-dollar concierge medicine membership, a thousand-dollar IV nutrient drip. The marketing across all of these is confident. The evidence behind all of these is not. Making a rational allocation decision requires a framework that most of this industry has no financial incentive to provide.10 min read Reconstitution basics — turning a lyophilized peptide vial into a usable solutionThe package arrives. Inside, there's a small vial containing what looks like nothing — a compressed disc of white powder sitting at the bottom of the glass, almost invisible. There's also a vial of clear liquid, labeled bacteriostatic water. Your instructions say to combine them. What happens between opening the box and filling your first syringe is called reconstitution, and it's one of the few steps in a peptide protocol where technique actually changes what you end up with.6 min read What "research peptide" labels really mean — and why they matter for what you're buyingYou're looking at two product pages side by side. Both sell the same compound — same name, similar molecular descriptions, roughly similar concentrations. One is priced at forty dollars. The other, from a licensed compounding pharmacy, requires a prescription and costs four times that. Both are described as "BPC-157" or "Tirzepatide" or whatever you went looking for. The cheaper one has a small line of text near the bottom of the page, easy to miss in the usual scan: "For research purposes only. Not for human consumption. Not intended for diagnostic or therapeutic use." You wonder if that language is just legal boilerplate, something every company puts up to cover themselves. It isn't.9 min read Subcutaneous injection 101 — what your prescribing provider already told you, in plain EnglishThe kit is on your kitchen counter. There's a small glass vial, a sealed syringe in a paper sleeve, two alcohol wipes, and a bright red sharps container that seems aggressively large given how small everything else is. Your prescribing provider went through this with you. Maybe a nurse walked you through it over the phone. But now it's just you and the counter, and the knowledge that you're about to inject yourself for the first time, and the instructions are somewhere in your email, and your brain has decided this is the moment to go completely blank.8 min read The supplement industry's peptide marketing problem — separating biology from claimsThe language arrives in a particular cadence. "Clinically proven." "Scientifically formulated." "Research-backed." "Doctor-recommended." It appears on product pages, in Instagram captions, in the brand's email sequence that follows you after you browse for five minutes. The words are arranged to evoke the authority of medicine while selling something that doesn't require any medical authority to produce, approve, or sell. In the peptide supplement space specifically, this gap between the vocabulary of clinical science and the actual evidentiary basis for the product has become wide enough to be worth examining directly.9 min read Telehealth peptide clinics — how to evaluate them criticallyYou search "peptide therapy" and the results produce forty-seven ads before the first non-promotional link. Clinics with polished landing pages, before-and-after photos, and urgency copy about limited enrollment. Some of them are legitimate medical practices. Some of them are marketing operations with a prescriber attached as an afterthought. The problem is that from the outside, at the search results level, they look nearly identical. Knowing what to look for underneath the surface isn't paranoia — it's the same due diligence you'd apply to any medical service.9 min read The supplement pile that isn't quite helping — when you've stacked too muchThe pill organizer is full. Not metaphorically — it takes a few minutes to fill it each week, and if you forget which compartment you filled you have to look at each one because you've lost track of the sequence. There's a multivitamin in there, because baseline seems sensible. Omega-3 because cardiovascular and inflammation. Magnesium because sleep, and also stress, and also because everyone seems to be taking magnesium now. Vitamin D. B-complex. Ashwagandha for cortisol, which you read about two years ago and kept going. An NAD precursor because mitochondria and aging. Collagen because joints and skin. Lion's mane because cognitive support. Some days a berberine capsule because metabolic health. The total lands somewhere between fifteen and twenty depending on the week and what you remembered to reorder. You've spent a meaningful amount of money on all of it. The honest answer to whether any of it is working is: you're not sure. If you stopped everything tomorrow, you don't know what would happen, and that uncertainty has become a reason not to stop. The doctor you mentioned it to said "most of those probably aren't doing anything," which is technically useful feedback but arrived without any guidance on which ones those were or what to do about it.8 min read The philosophy behind this library — what we're trying to do hereYou've read a few articles here and something is slightly different from what you expected. Maybe you came in thinking you'd find either an enthusiastic catalogue of compounds and protocols, or a cautious wall of disclaimers telling you to ask your doctor about everything. You found neither, quite. The articles explain mechanisms in real detail, they name what the evidence supports and what it doesn't, and they end somewhere other than a call to action. You're trying to figure out what this library actually is.9 min read Traveling with peptides — the practical logisticsThe trip is in two weeks. You've booked the flights, made the hotel reservation, and now you're staring at the protocol you've been following at home and realizing you'll need to bring all of it with you. The vial, the syringes, the alcohol wipes, the sharps container. You've gotten comfortable with the routine. Now the routine needs to travel.7 min read What to test before starting any peptide — the labwork that mattersYou've found a clinician, you have a protocol in mind, and someone has mentioned that you should get some labs done before starting. Maybe the clinic sent you a short requisition. Maybe you're wondering whether that short list is actually enough, or whether there's a more complete picture you should have before you begin. The honest answer is that most peptide protocols start with inadequate baseline labwork — not because the information doesn't matter, but because patients don't always know to push for it, and some clinics don't build their intake process around it.9 min read When not to take peptides — the scenarios where peptide protocols don't belongYou've read about BPC-157 and you're intrigued. Or someone you trust told you about a GH secretagogue protocol that changed how they feel, and now you're doing the research. Or you've already built a loose protocol in your head and you're mostly looking for confirmation. This is the moment worth pausing. Not because peptide protocols don't have a legitimate place in some people's health optimization work — they may — but because one of the most important questions in that work is the one almost nobody asks first: should I actually be doing this at all?9 min read When peptide stacks go wrong — the failure modes and how to recognize themIt starts reasonably. You add BPC-157 for a tendon issue, it seems to help, and you get interested. A few months later you're running BPC-157 and TB-500 together because someone on a forum explained the synergy. Then sermorelin for GH support. Then ipamorelin because the half-life stacks better with CJC-1295. Then Selank because the sermorelin is affecting your sleep. Then GHK-Cu for the skin benefit you read about. You're now six compounds in, spending more per month than your gym membership, injecting twice daily, and you can't quite articulate whether you feel better or just feel like you're doing something.9 min read When to escalate from peptide protocols to specialist evaluationYou've been on a peptide protocol for three months. The original complaint — persistent joint pain, slow recovery, poor sleep, cognitive fog — was real, you had a provider conversation, and the protocol seemed reasonable for what you were trying to address. But the symptom is still there. Or it changed but didn't resolve. Or you feel roughly the same and you're not sure whether that's the protocol working to maintain a baseline, or the protocol doing nothing, or something else going on that the protocol was never positioned to fix.9 min read When to stop a peptide protocol — the conditions that warrant reassessmentThere's a clear narrative for starting a peptide protocol. You do the research, you find a clinician, you get your labs, you start. The community around this space has well-worn language for beginning. Stopping, though, doesn't have the same story. The cultural pressure runs toward continuation — you've invested, you believe in the mechanism, you're waiting for the effect to arrive — and there's very little structure for the decision to stop or reassess. That asymmetry is worth examining directly, because it's where a lot of time and money quietly disappear.9 min read Why peptide companies disappear — and what that tells you about the marketYou found a supplier two or three years ago. The products seemed reliable, the customer service was responsive, the pricing was reasonable. You built a routine around them. Then one day you go to reorder and the site resolves to a parking page. The email address returns undeliverable. The Instagram account that used to post compound breakdowns and founder updates has been deleted or gone silent. If you search the company name, you find nothing recent — maybe a thread on a forum where several other people are asking the same question. They're gone.9 min read

← All articles